The AK3 Knockout A-549 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population derived from the A-549 human lung adenocarcinoma cell line, designed to disrupt the AK3 gene encoding mitochondrial GTP:AMP phosphotransferase. This knockout model abolishes AK3-dependent interconversion of GTP and AMP with GDP and ADP, offering a loss-of-function tool to investigate mitochondrial nucleotide metabolism. The polyclonal format ensures genetic heterogeneity, capturing a range of editing events across the population, which is suitable for bulk functional studies without clonal selection biases.
The parental A-549 cell line originates from a 58-year-old Caucasian male with lung adenocarcinoma and exhibits adherent epithelial morphology. Widely utilized in cancer research, A-549 cells serve as a robust model for studying non-small cell lung carcinoma biology, including tumor metabolism, drug response, and signal transduction. Their well-characterized mitochondrial function makes them particularly relevant for investigating metabolic pathways implicated in tumorigenesis.
AK3 (AK3L1) encodes a mitochondrial matrix enzyme that catalyzes the reversible reaction GTP + AMP ? GDP + ADP, critical for maintaining adenine and guanine nucleotide pools and supporting cellular energy homeostasis. AK3 operates within a network of adenylate kinases (AK1, AK2, AK4) and purine metabolism enzymes such as adenosine deaminase (ADA), AMP deaminase 3 (AMPD3), ecto-5′-nucleotidase (NT5E), ectonucleoside triphosphate diphosphohydrolase 1 (ENTPD1), and NME1. Its expression is transcriptionally regulated by PPARGC1A, NRF1, and TFAM, linking it to mitochondrial biogenesis programs. Functionally, AK3-derived ADP indirectly promotes AMPK activation, while its activity is coupled to oxidative phosphorylation and ATP synthesis through the adenine nucleotide translocator SLC25A4 (ANT1). Disruption of AK3 alters the equilibrated nucleotide pools, potentially perturbing AMPK signaling and mitochondrial respiratory capacity.
In the context of A-549 lung adenocarcinoma cells, AK3 knockout is predicted to compromise mitochondrial nucleotide homeostasis, impacting energy metabolism and potentially sensitizing cells to metabolic stress. This model enables dissection of how adenine and guanine nucleotide fluctuations influence AMPK-controlled metabolic checkpoints and proliferation under nutrient-limited conditions of the tumor microenvironment. As lung adenocarcinoma cells rewire mitochondrial pathways, loss of AK3 may expose targetable vulnerabilities or modulate chemotherapeutic responses, making it a valuable tool for cancer metabolism research.
Researchers can employ these polyclonal cells in diverse experiments: ATP/ADP ratio assays by HPLC or luminescence, Seahorse mitochondrial respiration profiling, and AMPK pathway activation studies under energy stress. Applications also include drug sensitivity screening, proliferation and apoptosis assays, and mitochondrial mass/network analysis by flow cytometry and immunofluorescence. Compatible with standard cell culture and molecular techniques such as Western blotting and RT-qPCR for AK3 expression. For product details, contact Ascent Research.
